|
|
|
Insider
Information: |
Goldstein Dov A Md |
Relationship: |
Director |
City: |
|
State: |
|
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
7 |
|
Direct
Shares |
113,515 |
|
Indirect Shares
|
9,937,297 |
|
|
Direct
Value |
$240,597 |
|
|
Indirect Value
|
$28,854,640 |
|
|
Total
Shares |
10,050,812 |
|
|
Total
Value |
$29,095,237 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Melinta Therapeutics, Inc |
MLNT |
Director |
2017-03-08 |
95 |
2017-03-08 |
0 |
Premium* |
|
ADMA Biologics Inc |
ADMA |
Director |
2020-02-28 |
7,500 |
2012-02-13 |
2,516,855 |
Premium* |
|
Durata Therapeutics, Inc. |
DRTX |
Director, 10% Owner |
2012-07-24 |
0 |
2012-07-24 |
3,130,824 |
Premium* |
|
Esperion Therapeutics, Inc. |
ESPR |
Director |
2018-06-06 |
47 |
2017-03-22 |
837,125 |
Premium* |
|
Loxo Oncology, Inc. |
LOXO |
CFO and Treasurer, 10%... |
2015-04-02 |
65,873 |
2015-04-02 |
3,452,493 |
Premium* |
|
Neubase Therapeutics Ord Shs |
NBSE |
Director |
2021-06-18 |
30,000 |
2020-04-30 |
0 |
Premium* |
|
Coya Therapeutics, Inc. |
COYA |
Director |
2023-01-03 |
10,000 |
2023-01-03 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
39 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 1 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2012-02-02 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
2,079,397 |
|
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and TreasurerOfficer |
|
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,656 |
|
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and TreasurerOfficer |
|
2014-07-31 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
188,707 |
|
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2012-02-07 |
4 |
B |
$6.00 |
$7,281,978 |
I/I |
1,213,663 |
3,293,060 |
2.1 |
- |
|
ADMA |
ADMA Biologics Inc |
Director |
|
2012-02-13 |
4 |
A |
$0.00 |
$0 |
I/I |
2,516,855 |
2,516,855 |
0 |
- |
|
DRTX |
Durata Therapeutics, Inc. |
Director |
|
2012-07-24 |
4 |
B |
$9.00 |
$9,999,999 |
I/I |
1,111,111 |
3,130,824 |
2.25 |
- |
|
DRTX |
Durata Therapeutics, Inc. |
Director |
|
2012-07-24 |
4 |
A |
$0.00 |
$0 |
I/I |
2,019,713 |
2,019,713 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2013-07-01 |
4 |
A |
$0.00 |
$0 |
I/I |
1,816,475 |
1,816,475 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2013-07-01 |
4 |
B |
$14.00 |
$3,333,666 |
I/I |
238,119 |
2,054,594 |
2.1 |
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
|
2014-08-06 |
4 |
B |
$13.00 |
$5,370,001 |
I/I |
413,077 |
3,452,493 |
2.64 |
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
|
2014-08-06 |
4 |
A |
$0.00 |
$0 |
I/I |
2,850,709 |
3,039,416 |
0 |
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
|
2015-04-01 |
4 |
OE |
$3.65 |
$253,249 |
D/D |
39,212 |
61,868 |
0 |
- |
|
LOXO |
Loxo Oncology, Inc. |
CFO and Treasurer |
|
2015-04-02 |
4 |
OE |
$3.65 |
$25,629 |
D/D |
4,005 |
65,873 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2015-04-23 |
4 |
S |
$109.10 |
$16,365,000 |
I/I |
(150,000) |
1,904,594 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2015-04-24 |
4 |
S |
$106.10 |
$7,169,373 |
I/I |
(67,469) |
1,837,125 |
0 |
- |
|
ESPR |
Esperion Therapeutics, In... |
Director |
|
2015-04-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(199,991) |
1,637,125 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2015-05-14 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,099,950) |
2,193,110 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2015-06-22 |
4 |
AS |
$35.74 |
$1,787,000 |
D/D |
(50,000) |
50 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2015-06-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,000 |
50,050 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2016-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
842 |
892 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2016-01-04 |
4 |
AS |
$30.06 |
$25,314 |
D/D |
(842) |
50 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2016-03-07 |
4 |
D |
$0.00 |
$0 |
I/I |
(999,955) |
1,193,060 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2017-01-05 |
4 |
S |
$3.20 |
$1,600,000 |
I/I |
(500,000) |
693,060 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2017-01-06 |
4 |
S |
$3.64 |
$1,592,864 |
I/I |
(437,600) |
255,460 |
0 |
- |
|
MLNT |
Melinta Therapeutics, Inc |
Director |
|
2017-01-13 |
4 |
S |
$3.40 |
$358,564 |
I/I |
(105,460) |
150,000 |
0 |
- |
|
39 Records found
|
|
Page 1 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|